MA30041B1 - Immunoglobulines - Google Patents
ImmunoglobulinesInfo
- Publication number
- MA30041B1 MA30041B1 MA31018A MA31018A MA30041B1 MA 30041 B1 MA30041 B1 MA 30041B1 MA 31018 A MA31018 A MA 31018A MA 31018 A MA31018 A MA 31018A MA 30041 B1 MA30041 B1 MA 30041B1
- Authority
- MA
- Morocco
- Prior art keywords
- immunoglobulin
- antibodies
- prophylaxis
- disorders
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
La présente invention concerne des anticorps contre NOGO, des formulations pharmaceutiques contenant ceux-ci et l'utilisation de tels anticorps dans le traitement et/ou la prophylaxie de maladies/troubles neurologiques.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0525662.3A GB0525662D0 (en) | 2005-12-16 | 2005-12-16 | Immunoglobulins |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30041B1 true MA30041B1 (fr) | 2008-12-01 |
Family
ID=35736284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31018A MA30041B1 (fr) | 2005-12-16 | 2008-06-11 | Immunoglobulines |
Country Status (31)
Country | Link |
---|---|
US (2) | US8362208B2 (fr) |
EP (2) | EP2228391A3 (fr) |
JP (1) | JP5015949B2 (fr) |
KR (1) | KR101355118B1 (fr) |
CN (1) | CN101374863B (fr) |
AR (1) | AR057239A1 (fr) |
AU (1) | AU2006325228B2 (fr) |
BR (1) | BRPI0619855A2 (fr) |
CA (1) | CA2633501C (fr) |
CR (1) | CR10099A (fr) |
CY (1) | CY1113094T1 (fr) |
DK (1) | DK1960429T3 (fr) |
EA (1) | EA015536B1 (fr) |
ES (1) | ES2389380T3 (fr) |
GB (1) | GB0525662D0 (fr) |
HK (1) | HK1119720A1 (fr) |
HR (1) | HRP20120684T1 (fr) |
IL (1) | IL192086A0 (fr) |
JO (1) | JO2795B1 (fr) |
MA (1) | MA30041B1 (fr) |
MY (1) | MY149492A (fr) |
NO (1) | NO20082699L (fr) |
NZ (1) | NZ569143A (fr) |
PE (1) | PE20071099A1 (fr) |
PL (1) | PL1960429T3 (fr) |
PT (1) | PT1960429E (fr) |
SI (1) | SI1960429T1 (fr) |
TW (1) | TWI378940B (fr) |
UA (1) | UA96279C2 (fr) |
WO (1) | WO2007068750A2 (fr) |
ZA (2) | ZA200805111B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2425768T3 (es) * | 2007-11-02 | 2013-10-17 | Novartis Ag | Moléculas de unión a nogo-a mejoradas y uso farmacéutico de las mismas |
ES2654937T3 (es) | 2008-04-02 | 2018-02-15 | Macrogenics, Inc. | Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos |
TW201012490A (en) | 2008-05-06 | 2010-04-01 | Glaxo Group Ltd | Encapsulation of biologically active agents |
JP2011527317A (ja) * | 2008-07-11 | 2011-10-27 | グラクソ グループ リミテッド | Nogo−aアンタゴニストによる筋萎縮性側索硬化症の治療 |
US8828390B2 (en) | 2010-07-09 | 2014-09-09 | Universitat Zurich | Uses of NOGO-A inhibitors and related methods |
AU2013285493A1 (en) | 2012-07-05 | 2015-01-22 | Glaxo Group Limited | Optimum dose regime of an anti-Nogo-A antibody in the treatment of amyotrophic lateral sclerosis |
US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
US11013815B2 (en) | 2017-06-14 | 2021-05-25 | Monojul, Llc | High-affinity anti-human folate receptor beta antibodies and methods of use |
US20230399390A1 (en) | 2019-10-24 | 2023-12-14 | Novago Therapeutics Ag | Novel anti-nogo-a antibodies |
GB202012331D0 (en) | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
WO2022263864A1 (fr) | 2021-06-17 | 2022-12-22 | Petmedix Ltd | Anticorps anti-cd20 canin |
WO2023067358A1 (fr) | 2021-10-21 | 2023-04-27 | Petmedix Ltd | Protéines comprenant le domaine extracellulaire de p75ntr |
CN116251181B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的注射制剂 |
WO2023152486A1 (fr) | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Anticorps thérapeutiques |
WO2024041450A1 (fr) * | 2022-08-22 | 2024-02-29 | 舒泰神(北京)生物制药股份有限公司 | Anticorps pour reconnaître de manière spécifique nogo-a et son utilisation |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5250414A (en) | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
GB9403250D0 (en) | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
NZ287442A (en) | 1994-05-27 | 1998-05-27 | Smithkline Beecham Spa | 4-substituted quinoline derivatives; medicaments; use as an nk3 receptor antagonist |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
DE69633336T2 (de) | 1995-06-27 | 2005-09-22 | Research Foundation Of Cuny | Zusamenzetzung enthaltend einen inhibitor des myelin assoziierten glycoproteins (mag), welcher einer veränderten oder mutierten form von mag enthält |
US6420338B1 (en) * | 1997-06-13 | 2002-07-16 | New York University Medical Center | Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
DK1098972T3 (da) | 1998-07-22 | 2011-01-03 | Smithkline Beecham Ltd | Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor |
AU774367C (en) | 1998-11-06 | 2005-04-21 | University Of Zurich | Nucleotide and protein sequences of nogo genes and methods based thereon |
FR2792199B3 (fr) | 1999-04-13 | 2001-05-18 | Sanofi Sa | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
WO2004006955A1 (fr) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Anticorps super humanises |
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
GB0318727D0 (en) | 2003-08-08 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
DE10338136A1 (de) | 2003-08-15 | 2005-03-24 | European Molecular Biology Laboratory | Zentrifuge und ein Träger zur Verwendung in einer Zentrifuge |
GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
WO2005061544A2 (fr) * | 2003-12-22 | 2005-07-07 | Glaxo Group Limited | Immunoglobulines |
AU2005207003C1 (en) * | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
US7973139B2 (en) * | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
-
2005
- 2005-12-16 GB GBGB0525662.3A patent/GB0525662D0/en not_active Ceased
-
2006
- 2006-12-14 US US12/097,279 patent/US8362208B2/en not_active Expired - Fee Related
- 2006-12-14 MY MYPI20082130A patent/MY149492A/en unknown
- 2006-12-14 CA CA2633501A patent/CA2633501C/fr not_active Expired - Fee Related
- 2006-12-14 JP JP2008545009A patent/JP5015949B2/ja not_active Expired - Fee Related
- 2006-12-14 AU AU2006325228A patent/AU2006325228B2/en not_active Ceased
- 2006-12-14 EA EA200801343A patent/EA015536B1/ru not_active IP Right Cessation
- 2006-12-14 PT PT06830633T patent/PT1960429E/pt unknown
- 2006-12-14 PE PE2006001607A patent/PE20071099A1/es not_active Application Discontinuation
- 2006-12-14 NZ NZ569143A patent/NZ569143A/en not_active IP Right Cessation
- 2006-12-14 ES ES06830633T patent/ES2389380T3/es active Active
- 2006-12-14 WO PCT/EP2006/069737 patent/WO2007068750A2/fr active Application Filing
- 2006-12-14 TW TW095146890A patent/TWI378940B/zh not_active IP Right Cessation
- 2006-12-14 CN CN2006800529521A patent/CN101374863B/zh not_active Expired - Fee Related
- 2006-12-14 UA UAA200807663A patent/UA96279C2/ru unknown
- 2006-12-14 PL PL06830633T patent/PL1960429T3/pl unknown
- 2006-12-14 SI SI200631393T patent/SI1960429T1/sl unknown
- 2006-12-14 DK DK06830633.1T patent/DK1960429T3/da active
- 2006-12-14 BR BRPI0619855-4A patent/BRPI0619855A2/pt not_active IP Right Cessation
- 2006-12-14 AR ARP060105524A patent/AR057239A1/es active IP Right Grant
- 2006-12-14 EP EP20100162457 patent/EP2228391A3/fr not_active Withdrawn
- 2006-12-14 EP EP06830633A patent/EP1960429B1/fr active Active
- 2006-12-14 KR KR1020087017348A patent/KR101355118B1/ko not_active IP Right Cessation
- 2006-12-24 JO JO2006457A patent/JO2795B1/en active
-
2008
- 2008-06-11 ZA ZA200805111A patent/ZA200805111B/xx unknown
- 2008-06-11 MA MA31018A patent/MA30041B1/fr unknown
- 2008-06-11 NO NO20082699A patent/NO20082699L/no not_active Application Discontinuation
- 2008-06-12 IL IL192086A patent/IL192086A0/en not_active IP Right Cessation
- 2008-06-20 CR CR10099A patent/CR10099A/es unknown
- 2008-12-08 HK HK08113307.3A patent/HK1119720A1/xx not_active IP Right Cessation
-
2009
- 2009-09-04 ZA ZA200906162A patent/ZA200906162B/en unknown
-
2012
- 2012-08-29 HR HRP20120684TT patent/HRP20120684T1/hr unknown
- 2012-09-05 CY CY20121100801T patent/CY1113094T1/el unknown
-
2013
- 2013-01-28 US US13/751,588 patent/US20130287781A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30041B1 (fr) | Immunoglobulines | |
MA28289A1 (fr) | Immunoglobulines | |
TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
MA30340B1 (fr) | Nouveaux composes | |
MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
MA27675A1 (fr) | Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
TNSN04268A1 (fr) | UTILISATION D'INHIBITEURS CETP ET FACULTATIVEMENT D'INHIBITEURS DE HMG -CoA - REDUCTASE ET/OU D'AGENTS ANTI-HYPERTENSIFS | |
MA30962B1 (fr) | Anticorps antifacteurs d'humanisés et leurs utilisations. | |
MA33381B1 (fr) | Proteine de liaison a il-13 | |
MA29931B1 (fr) | Inhibiteurs de la proteine d'activation de la 5-lipoxygenase (flap) | |
MA30914B1 (fr) | Dihydropyrazolones substituees utilisees dans le traitement de maladies cardiovasculaires et hematologiques. | |
MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
MA27668A1 (fr) | 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire | |
MA31767B1 (fr) | Composes organiques et leurs utilisations | |
MA29169B1 (fr) | Formulations intraveineuses d'inhibiteurs de la pde-5 | |
MA27794A1 (fr) | Dihydroquinazolines substituees a proprietes antivirales | |
MA32804B1 (fr) | Antagonistes d'isonicotinamide des récepteurs de l'orexine | |
EP1841426A4 (fr) | Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer | |
MA31845B1 (fr) | Pipéridino-dihydrothiénopyrimidines substituées | |
ES2616789T8 (es) | Inhibidores de tirosina cinasa de Bruton | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
MA31260B1 (fr) | 3-imidazolyl-indoles pour le traitement de maladies proliferatives | |
MA30353B1 (fr) | Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes. | |
ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen |